98 related articles for article (PubMed ID: 2506661)
21. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience.
Sloan MA; Price TR; Petito CK; Randall AM; Solomon RE; Terrin ML; Gore J; Collen D; Kleiman N; Feit F
Neurology; 1995 Apr; 45(4):649-58. PubMed ID: 7723950
[TBL] [Abstract][Full Text] [Related]
22. [Treatment trials of plasminogen activator (rt-PA) in central vein thrombosis of the retina].
Reim M; Bertram B; Wolf S
Klin Wochenschr; 1988; 66 Suppl 12():143-9. PubMed ID: 3126343
[TBL] [Abstract][Full Text] [Related]
23. Short-term response to thrombolytic therapy in deep venous thrombosis: predictive value of venographic appearance.
Meyerovitz MF; Polak JF; Goldhaber SZ
Radiology; 1992 Aug; 184(2):345-8. PubMed ID: 1620826
[TBL] [Abstract][Full Text] [Related]
24. Studies on the medical treatment of deep vein thrombosis.
Schulman S
Acta Med Scand Suppl; 1985; 704():1-68. PubMed ID: 3913282
[TBL] [Abstract][Full Text] [Related]
25. A pilot study of pro-urokinase in the treatment of deep vein thrombosis.
Moia M; Mannucci PM; Pini M; Prandoni P; Gurewich V
Thromb Haemost; 1994 Sep; 72(3):430-3. PubMed ID: 7531876
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke.
Amaro S; Soy D; Obach V; Cervera A; Planas AM; Chamorro A
Stroke; 2007 Jul; 38(7):2173-5. PubMed ID: 17525395
[TBL] [Abstract][Full Text] [Related]
27. Intermittent regional therapy with rt-PA is not superior to systemic thrombolysis in deep vein thrombosis (DVT)--a German multicenter trial.
Schwieder G; Grimm W; Siemens HJ; Flor B; Hilden A; Gmelin E; Friedrich HJ; Wagner T
Thromb Haemost; 1995 Nov; 74(5):1240-3. PubMed ID: 8607102
[TBL] [Abstract][Full Text] [Related]
28. Successful systemic low-dose lysis of a caval thrombus by rt-PA in a neonate with congenital nephrotic syndrome.
Kändler C; Ries M; Rupprecht T; Ruder H; Harms D
J Pediatr Hematol Oncol; 1997; 19(4):348-50. PubMed ID: 9256836
[TBL] [Abstract][Full Text] [Related]
29. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
[TBL] [Abstract][Full Text] [Related]
30. A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.
Gold HK; Johns JA; Leinbach RC; Yasuda T; Grossbard E; Zusman R; Collen D
Circulation; 1987 Jun; 75(6):1192-9. PubMed ID: 3105913
[TBL] [Abstract][Full Text] [Related]
31. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
[TBL] [Abstract][Full Text] [Related]
32. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
Martin U; Fischer S; Sponer G
J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
[TBL] [Abstract][Full Text] [Related]
33. Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial.
Williams DO; Topol EJ; Califf RM; Roberts R; Mancini GB; Joelson JM; Ellis SG; Kleiman NS
Circulation; 1990 Aug; 82(2):376-83. PubMed ID: 2115407
[TBL] [Abstract][Full Text] [Related]
34. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy.
Marder VJ; Soulen RL; Atichartakarn V; Budzynski AZ; Parulekar S; Kim JR; Edward N; Zahavi J; Algazy KM
J Lab Clin Med; 1977 May; 89(5):1018-29. PubMed ID: 323387
[TBL] [Abstract][Full Text] [Related]
35. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Collen D; Stassen JM; De Cock F
Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
[TBL] [Abstract][Full Text] [Related]
36. Recombinant tissue-type plasminogen activator followed by heparin compared with heparin alone for refractory unstable angina pectoris.
Ardissino D; Barberis P; De Servi S; Mussini A; Rolla A; Visani L; Specchia G
Am J Cardiol; 1990 Oct; 66(12):910-4. PubMed ID: 2121016
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Zabramski JM; Spetzler RF; Lee KS; Papadopoulos SM; Bovill E; Zimmerman RS; Bederson JB
J Neurosurg; 1991 Aug; 75(2):189-96. PubMed ID: 1906534
[TBL] [Abstract][Full Text] [Related]
38. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.
Eriksson BI; Ekman S; Lindbratt S; Baur M; Bach D; Torholm C; Kälebo P; Close P
J Bone Joint Surg Am; 1997 Mar; 79(3):326-33. PubMed ID: 9070519
[TBL] [Abstract][Full Text] [Related]
39. Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial.
Van de Werf F
J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):14A-19A. PubMed ID: 3142943
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction.
Kalbfleisch J; Thadani U; LittleJohn JK; Brown G; Magorien R; Kutcher M; Taylor G; Maddox WT; Campbell WB; Perry J
Am J Cardiol; 1992 May; 69(14):1120-7. PubMed ID: 1575179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
